Celldex Therapeutics (NASDAQ:CLDX) Shares Up 4.8% - Still a Buy?

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report)'s stock price traded up 4.8% on Monday . The company traded as high as $19.30 and last traded at $19.18. 182,257 shares traded hands during trading, a decline of 79% from the average session volume of 880,619 shares. The stock had previously closed at $18.30.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. UBS Group assumed coverage on shares of Celldex Therapeutics in a research report on Thursday, February 13th. They issued a "buy" rating and a $44.00 price objective on the stock. The Goldman Sachs Group reduced their price objective on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research note on Monday, March 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Friday, February 28th. Cantor Fitzgerald reissued an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Finally, Morgan Stanley initiated coverage on Celldex Therapeutics in a research report on Thursday, March 20th. They set an "overweight" rating and a $46.00 price target on the stock. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $54.33.

Celldex Therapeutics Stock Performance

The business has a fifty day moving average of $19.27 and a two-hundred day moving average of $23.61. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -7.51 and a beta of 1.59.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.02. The company had revenue of $1.18 million for the quarter, compared to analyst estimates of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. As a group, sell-side analysts predict that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Celldex Therapeutics

Several hedge funds have recently bought and sold shares of CLDX. Vanguard Group Inc. lifted its holdings in Celldex Therapeutics by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company's stock worth $98,098,000 after purchasing an additional 12,213 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Celldex Therapeutics by 23.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock valued at $89,890,000 after acquiring an additional 676,771 shares in the last quarter. Point72 Asset Management L.P. increased its position in Celldex Therapeutics by 50.8% during the fourth quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock worth $63,579,000 after acquiring an additional 847,264 shares during the period. Deep Track Capital LP acquired a new stake in Celldex Therapeutics in the 4th quarter worth about $38,919,000. Finally, Rock Springs Capital Management LP boosted its holdings in Celldex Therapeutics by 10.7% in the 4th quarter. Rock Springs Capital Management LP now owns 1,222,182 shares of the biopharmaceutical company's stock valued at $30,885,000 after purchasing an additional 118,404 shares during the period.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.